|Videos|June 17, 2015
Phase I Immunotherapy Trials
Advertisement
Episodes in this series
Advertisement
Related to this article
The phase 3 OptiTROP-Lung06 trial showed a PFS improvement with sac-TMT plus pembrolizumab in PD-L1–negative NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Bioequivalent Olaparib Across Previously Approved Cancer Indications
2
Longer-Term Data Help Shape TKI Selection in ROS1+ and ALK+ NSCLC
3
Experts Revisit the Most Notable Data in GU Oncology From ASCO 2026
4
Alpha DaRT Plus Pembrolizumab Yields 100% ORR in Elderly Recurrent or Metastatic HNSCC
5